SCHEMBL5402056

SCHEMBL5402056

CC(=O)Nc1ccc(S(=O)(=O)Nc2nnc(CC(C)(C)C)s2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 1.00
KMT2A Q03164 5/20 1.00
GAA P10253 1/20 1.00
MAPT P10636 1/20 1.00
MAPK1 P28482 1/20 1.00
AKT1 P31749 2/20 0.77
ALDH1A1 P00352 6/20 0.72
PKM P14618 3/20 0.69
HSD17B10 Q99714 3/20 0.69
HPGD P15428 1/20 0.69
CA1 P00915 1/20 0.63
CA2 P00918 1/20 0.63
CA9 Q16790 1/20 0.63
KLKB1 P03952 1/20 0.58
CTSB P07858 1/20 0.58
ELANE P08246 1/20 0.58
P2RY1 P47900 1/20 0.58
APEX1 P27695 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL282800 0.87 AKT1 (0.82) MEN1KMT2AGAAMAPTMAPK1
SCHEMBL287025 0.87 AKT1 (1.00) MEN1KMT2AGAAMAPTMAPK1
SCHEMBL282833 0.85 AKT1 (0.78) MEN1KMT2AGAAMAPTMAPK1
SCHEMBL11891683 0.84 AKT1 (0.77) MEN1KMT2AGAAMAPTMAPK1
SCHEMBL10108459 0.84 AKT1 (0.80) MEN1KMT2AGAAMAPTMAPK1
SCHEMBL286763 0.82 ALDH1A1 (1.00) MEN1KMT2AGAAMAPTMAPK1
SCHEMBL5389533 0.82 ALDH1A1 (1.00) MEN1KMT2AGAAMAPTMAPK1
SCHEMBL5396055 0.82 ALDH1A1 (0.77) MEN1KMT2AGAAMAPTMAPK1
SCHEMBL5392537 0.81 ALDH1A1 (1.00) MEN1KMT2AGAAMAPTMAPK1
SCHEMBL286629 0.80 ALDH1A1 (0.71) MEN1KMT2AGAAMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 US disclosed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US disclosed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 EP disclosed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US disclosed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 MEN1 942/4885KMT2A 3325/4885GAA 364/4885
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD17B11 MEN1 974/4885KMT2A 3281/4885GAA 727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.